Kailera walks path paved by Lilly in post-IPO ‘catalyst-rich period’ at Tristan Manalac

Location: Unknown.

Employment type: full-time.

Key skills: GLP.

Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirrors Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1 like Foundayo and a triple-G therapy like retatrutide.